ArticleDrugs - real world outcomes2026
Time to Treatment Discontinuation and Cost Effectiveness of Third-Line Therapies in Advanced Colorectal Cancer: Real-World Evidence from the NIH All of Us Research Program.
Patrick J Kiel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.